BIOMAT Database Logo BIOMAT Database Logo

Colistin resistance mechanisms in Gram-negative bacteria: a Focus on Escherichia coli. 2023

Mohammad Abavisani, and Narjess Bostanghadiri, and Hossein Ghahramanpour, and Mansoor Kodori, and Fariba Akrami, and Hadis Fathizadeh, and Ali Hashemi, and Mohsen Rastegari-Pouyani
Student Research Committee, Mashhad University of Medical Sciences, 9138813944 Mashhad, Iran.

Multidrug-resistant (MDR) Escherichia coli strains have rapidly increased worldwide, and effective antibiotic therapeutic options are becoming more restricted. As a polymyxin antibiotic, colistin has a long history of usage, and it is used as a final line of treatment for severe infections by Gram-negative bacteria (GNB) with high-level resistance. However, its application has been challenged by the emergence of E. coli colistin resistance. Hence, determining the mechanism that confers colistin resistance is crucial for monitoring and controlling the dissemination of colistin-resistant E. coli strains. This comprehensive review summarizes colistin resistance mechanisms in E. coli strains and concentrates on the history, mode of action, and therapeutic implications of colistin. We have mainly focused on the fundamental mechanisms of colistin resistance that are mediated by chromosomal or plasmid elements and discussed major mutations in the two-component systems (TCSs) genes and plasmids that transmit the mobilized colistin resistance resistant genes in E. coli strains.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D003091 Colistin Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally. Polymyxin E,Colimycin,Colisticin,Colistin Sulfate,Coly-Mycin,Totazina,Sulfate, Colistin
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D024881 Drug Resistance, Bacterial The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance, Bacterial,Antibacterial Drug Resistance
D029968 Escherichia coli Proteins Proteins obtained from ESCHERICHIA COLI. E coli Proteins

Related Publications

Mohammad Abavisani, and Narjess Bostanghadiri, and Hossein Ghahramanpour, and Mansoor Kodori, and Fariba Akrami, and Hadis Fathizadeh, and Ali Hashemi, and Mohsen Rastegari-Pouyani
Disrupting iron homeostasis can potentiate colistin activity and overcome colistin resistance mechanisms in Gram-Negative Bacteria.
September 2023, Communications biology,
Mohammad Abavisani, and Narjess Bostanghadiri, and Hossein Ghahramanpour, and Mansoor Kodori, and Fariba Akrami, and Hadis Fathizadeh, and Ali Hashemi, and Mohsen Rastegari-Pouyani
Preservation of Acquired Colistin Resistance in Gram-Negative Bacteria.
January 2016, Antimicrobial agents and chemotherapy,
Mohammad Abavisani, and Narjess Bostanghadiri, and Hossein Ghahramanpour, and Mansoor Kodori, and Fariba Akrami, and Hadis Fathizadeh, and Ali Hashemi, and Mohsen Rastegari-Pouyani
Resistance mechanisms in Gram-negative bacteria.
July 2022, Medicina intensiva,
Mohammad Abavisani, and Narjess Bostanghadiri, and Hossein Ghahramanpour, and Mansoor Kodori, and Fariba Akrami, and Hadis Fathizadeh, and Ali Hashemi, and Mohsen Rastegari-Pouyani
Colistin and tigecycline resistance in carbapenemase-producing Gram-negative bacteria: emerging resistance mechanisms and detection methods.
September 2016, Journal of applied microbiology,
Mohammad Abavisani, and Narjess Bostanghadiri, and Hossein Ghahramanpour, and Mansoor Kodori, and Fariba Akrami, and Hadis Fathizadeh, and Ali Hashemi, and Mohsen Rastegari-Pouyani
Resistance mechanisms for Gram-negative bacteria-specific lipopeptides, turnercyclamycins, differ from that of colistin.
December 2023, Microbiology spectrum,
Mohammad Abavisani, and Narjess Bostanghadiri, and Hossein Ghahramanpour, and Mansoor Kodori, and Fariba Akrami, and Hadis Fathizadeh, and Ali Hashemi, and Mohsen Rastegari-Pouyani
Tryptamine derivatives disarm colistin resistance in polymyxin-resistant gram-negative bacteria.
May 2019, Bioorganic & medicinal chemistry,
Mohammad Abavisani, and Narjess Bostanghadiri, and Hossein Ghahramanpour, and Mansoor Kodori, and Fariba Akrami, and Hadis Fathizadeh, and Ali Hashemi, and Mohsen Rastegari-Pouyani
Beta-lactam resistance mechanisms in gram-negative bacteria.
November 1986, Microbiological sciences,
Mohammad Abavisani, and Narjess Bostanghadiri, and Hossein Ghahramanpour, and Mansoor Kodori, and Fariba Akrami, and Hadis Fathizadeh, and Ali Hashemi, and Mohsen Rastegari-Pouyani
Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units.
April 2013, Intensive care medicine,
Mohammad Abavisani, and Narjess Bostanghadiri, and Hossein Ghahramanpour, and Mansoor Kodori, and Fariba Akrami, and Hadis Fathizadeh, and Ali Hashemi, and Mohsen Rastegari-Pouyani
Effects of Efflux Pump Inhibitors on Colistin Resistance in Multidrug-Resistant Gram-Negative Bacteria.
May 2016, Antimicrobial agents and chemotherapy,
Mohammad Abavisani, and Narjess Bostanghadiri, and Hossein Ghahramanpour, and Mansoor Kodori, and Fariba Akrami, and Hadis Fathizadeh, and Ali Hashemi, and Mohsen Rastegari-Pouyani
Alternative periplasmic copper-resistance mechanisms in Gram negative bacteria.
July 2009, Molecular microbiology,
Copied contents to your clipboard!